EW
Same story, new stamp of approval
TD Cowen isn’t changing the script here — it’s just slapping a fresh "Buy" label on Edwards Lifesciences and holding the price target at $97. That’s about 20% above the stock’s recent $80.86 level, so the message is pretty clear: the Street still thinks Edwards has room to run.
Why the bulls are still nodding
The real engine here is transcatheter aortic valve replacement, or TAVR if you like your healthcare jargon with fewer syllables. TD Cowen pointed to market share gains in TAVR, plus momentum in transcatheter mitral and tricuspid therapies. In plain English: Edwards is still carving out more territory in the world of minimally invasive heart procedures, and that can mean a prettier growth story for a company built around medical-device precision rather than viral consumer buzz.
Why investors should care
Analyst reiterations aren’t exactly fireworks, but they matter when they reinforce a stock’s core thesis. If Edwards keeps gaining share in a large, durable market, that can help support revenue growth and keep margins healthy — the kind of combo that tends to make portfolio managers stop scrolling and pay attention.
Big picture
No drama, no downgrade, no surprise — just another reminder that Edwards’ heart-valve franchise still has believers on Wall Street. In a market that loves a clean growth narrative, that’s not nothing.